Viking Therapeutics is stepping into the spotlight this December. The metabolic-drug developer will share updates, answer investor questions, and highlight the progress of its leading programs.
Quick Highlights
- Event: Piper Sandler 37th Annual Healthcare Conference
- Dates: December 2–4, 2025
- Fireside Chat: December 2, 2025, from 12:30 to 12:55 p.m. ET
- Location: New York City
- Format: Fireside chat + investor meetings
Why This Matters?
Viking is running some of the most closely watched trials in metabolic and endocrine disorders. The conference gives investors a front-row seat to the company’s latest data and direction.
Inside Viking Therapeutics: What the Company Is Building
Viking focuses on first-in-class and best-in-class therapies for tough metabolic diseases. Their programs target obesity, NASH, NAFLD, lipid disorders, and rare metabolic conditions.
VK2735: Dual GLP-1/GIP Agonist
VK2735 is Viking’s flagship program.
- It activates GLP-1 and GIP receptors, two powerful metabolic pathways.
- Phase 1 and Phase 2 data show strong tolerability and promising metabolic benefits.
- Viking is running two formats: subcutaneous injections and an oral formulation now in Phase 2.
This program positions Viking inside the fastest-moving category in metabolic drug development.
VK2809: Selective Thyroid Hormone Receptor-Beta Agonist
VK2809 aims to solve lipid and liver-fat disorders with precision.
- It succeeded in a Phase 2b trial for biopsy-confirmed NASH and fibrosis.
- A Phase 2a NAFLD study showed meaningful drops in LDL-C and liver fat versus placebo.
- The drug is orally available, which adds convenience and adherence advantages.
DACRAs: The New Obesity Frontier
Viking is also working on dual amylin and calcitonin receptor agonists (DACRAs).
These agents may shape the next generation of obesity therapies by targeting appetite, satiety, and energy balance through multiple hormonal pathways.
VK0214: Rare Disease Focus
VK0214 targets X-linked adrenoleukodystrophy (X-ALD).
- It modulates the thyroid hormone receptor-beta pathway.
- Phase 1b results showed strong tolerability and significant reductions in VLCFAs.
- Early data signal potential disease modification for the AMN form of X-ALD.
